A Phase 3 interventional study of Florbetaben (BAY94-9172) in Alzheimer Disease, sponsored by Lantheus Biosciences Ltd.. Completed at 19 sites in 5 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Lantheus Biosciences Ltd. (part of Lantheus Holdings, Inc.) · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 397th largest by enrollment of the 1,611 interventional ones that give a count, is one of 88 that started in 2009, is one of 188 in phase 3, and was the 381st registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,942 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 88 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 218 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,611 interventional studies, 160 across the 309 observational. Of the 1,378 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,942 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lantheus Biosciences Ltd., one of the names counted as Lantheus Holdings, Inc.. Under that name alone:
Lantheus Biosciences Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Lantheus Holdings, Inc. has 7 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
166 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 166 to your calendar (.ics) → With an account.
Among the 1,942 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective histopathologic post mortem specimens as the standard of truth
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Florbetaben (BAY94-9172)
Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral Beta-amyloid in Postmortem Specimens
The sensitivity/specificity of the visual assessment were calculated based on the majority read assessment of regional tracer uptake. This result was derived from assessments by 3 independent readers for brain regions of a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was a centralized histopathological determination of β-amyloid presence/absence based on both Bielschowsky silver and immunohistochemical staining. Based on the PET images, a brain region was classified as "normal" or "abnormal" depending on the presence or absence of regional tracer uptake in the respective region. "Normal" therefore meant absence of β-amyloid and "abnormal" presence of β-amyloid. Sensitivity was defined as the percentage of abnormal brain regions from all regions where an SOT was available and the SOT was "β-amyloid present". Specificity was defined as the percentage of normal brain regions from all regions where an SOT was available and was "β-amyloid not present".
Time frame: 90-110 minutes post injection (PET image acquisition)
Sensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification With Bielschowsky Silver Staining (SOT 1).
Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a centralized histopathological assessment of the presence/absence of β-amyloid based on Bielschowsky silver staining (SOT 1). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".
Time frame: 90-110 minutes post injection (PET image acquisition)
Sensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With Histopathological Verification With Bielschowsky Silver Staining and Immunohistochemistry (SOT 2).
Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a centralized histopathological assessment of the presence/absence of β-amyloid based on Bielschowsky silver staining and immunohistochemistry (SOT 2). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".
Time frame: 90-110 minutes post injection (PET image acquisition)
Sensitivity and Specificity of the Majority Read "Whole Brain" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification According to CERAD Criteria (SOT 3).
Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a histopathological assessment of the presence/absence of β-amyloid according to CERAD Criteria (SOT 3). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".
Time frame: 90-110 minutes post injection (PET image acquisition)
Sensitivity and Specificity of the Subject Level Composite SUVR Calculated Based on Pathology Results.
Sensitivity and specificity of subject level composite Standard Uptake Value Ratios (SUVR) by SOT for subjects with available brain tissue and 10 healthy volunteers. The SUVR were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of the tissue radioactivity concentration c (in MBq/kg) at time point t, and the injected activity (in MBq), extrapolated to the same time (t) divided by the body weight (in kg). SUV numbers were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference. SOTs comprised Bielschowsky silver staining (SOT 1), Bielschowsky silver staining with immunohistochemistry (SOT 2) and neuropathology assessment according to CERAD (SOT 3). SUVR analysis was performed for baseline and available follow-up scans. The optimal threshold for the distinction between β-amyloid present yes/no according to the respective SOT was derived based on ROC curve analyses and used to calculate sensitivity and specificity.
Time frame: 90-110 minutes post injection (PET image acquisition)
Subject Level Composite SUVRs by SOT for Baseline and Available Follow-Up Scans
Subject level composite SUVRs (calculated as mean of SUVRs from the frontal, parietal, lateral temporal, anterior and posterior cingulate, and occipital cortices) by SOT are reported for subjects with available brain tissue. The initial drug administration group includes additionally 10 healthy controls who were considered as ß-amyloid negative. The SOTs for deceased subjects were based on Bielschowsky silver staining (SOT 1), Bielschowsky silver staining in combination with immunohistochemistry (SOT 2) and neuropathology assessment according to CERAD (SOT 3). SUVR analysis was performed for baseline and available follow-up scans.
Time frame: 90-110 minutes post injection (PET image acquisition)
Subjects were screened at 15 study centers in Australia, Germany, France, Japan, and the U.S.
| Milestone | All Study Participants |
|---|---|
| Started | 218 |
| Safety analysis set | 216 |
| Interim analysis set (primary efficacy) | 41 |
| Final analysis set (whole brain) | 97 |
| First annual repeat injection | 91 |
| Second annual repeat injection | 34 |
| Completed | 35 |
| Not completed | 183 |
| Withdrew: Death | 90 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Most common: study ended by sponsor | 77 |
The sensitivity/specificity of the visual assessment were calculated based on the majority read assessment of regional tracer uptake. This result was derived from assessments by 3 independent readers for brain regions of a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was a centralized histopathological determination of β-amyloid presence/absence based on both Bielschowsky silver and immunohistochemical staining. Based on the PET images, a brain region was classified as "normal" or "abnormal" depending on the presence or absence of regional tracer uptake in the respective region. "Normal" therefore meant absence of β-amyloid and "abnormal" presence of β-amyloid. Sensitivity was defined as the percentage of abnormal brain regions from all regions where an SOT was available and the SOT was "β-amyloid present". Specificity was defined as the percentage of normal brain regions from all regions where an SOT was available and was "β-amyloid not present".
| percentage of regions | Sensitivity (Interim Analysis Set) | Specificity (Interim Analysis Set) |
|---|---|---|
| Total | 77.36 | 94.20 |
| Frontal Cortex | 85.71 | 95.00 |
| Occipital Cortex | 88.89 | 86.36 |
| Hippocampus | 57.14 | 100.00 |
| Anterior Cingulate Cortex | 90.00 | 85.71 |
| Posterior Cingulate Cortex | 81.82 | 94.44 |
| Cerebellar Cortex | 0.00 | 100.00 |
Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a centralized histopathological assessment of the presence/absence of β-amyloid based on Bielschowsky silver staining (SOT 1). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".
| percentage of subjects | Full Analysis Set Final Clinical Study Report |
|---|---|
| Sensitivity | 96.49 (91.71 to 100.00) |
| Specificity | 85.00 (73.93 to 96.07) |
Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a centralized histopathological assessment of the presence/absence of β-amyloid based on Bielschowsky silver staining and immunohistochemistry (SOT 2). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".
| percentage of subjects | Full Analysis Set Final Clinical Study Report |
|---|---|
| Sensitivity | 96.72 (92.25 to 100.00) |
| Specificity | 94.44 (86.96 to 100.00) |
Sensitivity and specificity of the whole brain visual assessment were calculated. Any brain with a region classified as abnormal from PET imaging was to be classified as abnormal for the "whole brain" assessment. This result was derived from assessments by 3 independent readers for a subject where a Standard of Truth (SOT) was available. The SOT for this analysis was based on a histopathological assessment of the presence/absence of β-amyloid according to CERAD Criteria (SOT 3). The sensitivity was defined as the proportion of brains classified as abnormal from all brains where this SOT was available and was "β-amyloid present". The specificity was defined as the proportion of brains classified as normal from all brains where this SOT was available and was "β-amyloid not present".
| percentage of subjects | Full Analysis Set Final Clinical Study Report |
|---|---|
| Sensitivity | 96.49 (91.71 to 100.00) |
| Specificity | 85.00 (73.93 to 96.07) |
Sensitivity and specificity of subject level composite Standard Uptake Value Ratios (SUVR) by SOT for subjects with available brain tissue and 10 healthy volunteers. The SUVR were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of the tissue radioactivity concentration c (in MBq/kg) at time point t, and the injected activity (in MBq), extrapolated to the same time (t) divided by the body weight (in kg). SUV numbers were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference. SOTs comprised Bielschowsky silver staining (SOT 1), Bielschowsky silver staining with immunohistochemistry (SOT 2) and neuropathology assessment according to CERAD (SOT 3). SUVR analysis was performed for baseline and available follow-up scans. The optimal threshold for the distinction between β-amyloid present yes/no according to the respective SOT was derived based on ROC curve analyses and used to calculate sensitivity and specificity.
| percentage of subjects | Sensitivity of Subject Level Composite SUVR by SOT | Specificity of Subject Level Composite SUVR by SOT |
|---|---|---|
| SOT 1 (initial period) | 89 | 82 |
| SOT 2 (initial period) | 90 | 91 |
| SOT 3 (initial period) | 89 | 90 |
| SOT 1 (last available scan) | 88 | 85 |
| SOT 2 (last available scan) | 89 | 94 |
| SOT 3 (last available scan) | 95 | 87 |
Subject level composite SUVRs (calculated as mean of SUVRs from the frontal, parietal, lateral temporal, anterior and posterior cingulate, and occipital cortices) by SOT are reported for subjects with available brain tissue. The initial drug administration group includes additionally 10 healthy controls who were considered as ß-amyloid negative. The SOTs for deceased subjects were based on Bielschowsky silver staining (SOT 1), Bielschowsky silver staining in combination with immunohistochemistry (SOT 2) and neuropathology assessment according to CERAD (SOT 3). SUVR analysis was performed for baseline and available follow-up scans.
| Standardized Uptake Value Ratio (SUVR) | Initial Drug Administration | 1st Repeat Drug Administration | 2nd Repeat Drug Administration |
|---|---|---|---|
| SOT 1 (abeta absent) | 1.296 ± 0.232 | 1.319 ± 0.414 | 1.537 ± NA |
| SOT 1 (abeta present) | 1.707 ± 0.276 | 1.625 ± 0.250 | 1.699 ± 0.046 |
| SOT 2 (abeta absent) | 1.237 ± 0.140 | 1.175 ± 0.364 | 1.537 ± NA |
| SOT 2 (abeta present) | 1.714 ± 0.273 | 1.632 ± 0.244 | 1.699 ± 0.046 |
| SOT 3 (abeta absent) | 1.263 ± 0.170 | 1.260 ± 0.390 | NA ± NA |
| SOT 3 (abeta present) | 1.729 ± 0.270 | 1.639 ± 0.236 | 1.645 ± 0.099 |
Collected over All treatment emergent adverse events were recorded within 7 days of the application or follow-up application of study drug.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Initial Drug Administration | — | 12/216 (5.6%) | 48/216 (22.2%) |
| 1st Repeat Drug Administration | — | 0/91 (0%) | 22/91 (24.2%) |
| 2nd Repeat Drug Administration | — | 0/34 (0%) | 14/34 (41.2%) |
| Event | Initial Drug Administration | 1st Repeat Drug Administration | 2nd Repeat Drug Administration |
|---|---|---|---|
| Frontotemporal dementiaNervous system disorders | 1/216 | 0/91 | 0/34 |
| Dementia, Alzheimers' typeNervous system disorders | 1/216 | 0/91 | 0/34 |
| ColitisGastrointestinal disorders | 1/216 | 0/91 | 0/34 |
| PneumoniaInfections and infestations | 1/216 | 0/91 | 0/34 |
| Spinal compression fractureMusculoskeletal and connective tissue disorders | 1/216 | 0/91 | 0/34 |
| Pneumonia aspirationInfections and infestations | 1/216 | 0/91 | 0/34 |
| Pubis fractureInjury, poisoning and procedural complications | 1/216 | 0/91 | 0/34 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/216 | 0/91 | 0/34 |
| Colon cancerGastrointestinal disorders | 1/216 | 0/91 | 0/34 |
| Hepatic cancer metastaticHepatobiliary disorders | 1/216 | 0/91 | 0/34 |
| Event | Initial Drug Administration | 1st Repeat Drug Administration | 2nd Repeat Drug Administration |
|---|---|---|---|
| HaematomaVascular disorders | 1/216 | 5/91 | 6/34 |
| ErythemaSkin and subcutaneous tissue disorders | 1/216 | 4/91 | 3/34 |
| Injection site hemorrhageGeneral disorders | 1/216 | 4/91 | 2/34 |
| Injection site hematomaGeneral disorders | 10/216 | 1/91 | 0/34 |
| Puncture site reactionGeneral disorders | 7/216 | 4/91 | 0/34 |
| Haemorrhage subcutaneousSkin and subcutaneous tissue disorders | 1/216 | 3/91 | 1/34 |
| PyrexiaGeneral disorders | 7/216 | 2/91 | 0/34 |
| Injection site erythemaGeneral disorders | 4/216 | 0/91 | 1/34 |
| HypertensionVascular disorders | 5/216 | 1/91 | 1/34 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/216 | 0/91 | 1/34 |
Participants in the safety analysis set were treated with study drug.
| Age, Continuous(years) | Safety Analysis Set |
|---|---|
| Mean | 74.4 ± 15.4 |
| Sex: Female, Male(Participants) | Safety Analysis Set |
|---|---|
| Female | 104 |
| Male | 112 |
| Ethnicity (NIH/OMB)(Participants) | Safety Analysis Set |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 213 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Safety Analysis Set |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 55 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 159 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| BMI (kg/m^2)(kg/m^2) | Safety Analysis Set |
|---|---|
| Mean | 23.617 ± 5.213 |
| Body weight(kg) | Safety Analysis Set |
|---|---|
| Mean | 64.95 ± 18.44 |
| Height(cm) | Safety Analysis Set |
|---|---|
| Mean | 164.70 ± 12.34 |
| Baseline clinical diagnosis(participants) | Safety Analysis Set |
|---|---|
| Alzheimer's Disease | 137 |
| Dementia with Lewy bodies | 5 |
| Other dementia subject | 31 |
| Healthy volunteers | 32 |
| Healthy negative control | 11 |
The record gives a start of Nov 2009, a primary completion of Sep 2011 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 3 years 6 months after primary completion. A results delay was requested in May 2013.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Florbetaben f-18